Search

Your search keyword '"Wildiers H"' showing total 1,129 results
Start Over Author "Wildiers H"
1,129 results on '"Wildiers H"'

1. Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data

Author

Izci H, Macq G, Tambuyzer T, De Schutter H, Wildiers H, Duhoux FP, de Azambuja E, Taylor D, Staelens G, Orye G, Hlavata Z, Hellemans H, De Rop C, Neven P, and Verdoodt F

Subjects
machine learning, breast cancer, distant metastases, recurrences, algorithm, administrative data, Infectious and parasitic diseases, RC109-216
Abstract

Hava Izci,1 Gilles Macq,2 Tim Tambuyzer,2 Harlinde De Schutter,2 Hans Wildiers,1,3 Francois P Duhoux,4 Evandro de Azambuja,5 Donatienne Taylor,6 Gracienne Staelens,7 Guy Orye,8 Zuzana Hlavata,9 Helga Hellemans,10 Carine De Rop,11 Patrick Neven,1,3 Freija Verdoodt2 1KU Leuven - University of Leuven, Department of Oncology, Leuven, B-3000, Belgium; 2Belgian Cancer Registry, Research Department, Brussels, Belgium; 3University Hospitals Leuven, Multidisciplinary Breast Center, Leuven, B-3000, Belgium; 4Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium; 5Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, Belgium; 6CHU UCL Namur, Site Sainte-Elisabeth, Namur, Belgium; 7Multidisciplinary Breast Center, General Hospital Groeninge, Kortrijk, Belgium; 8Department of Obstetrics and Gynecology, Jessa Hospital, Hasselt, Belgium; 9Department of Medical Oncology, CHR Mons-Hainaut, Mons, Hainaut, Belgium; 10Department of Obstetrics and Gynaecology, AZ Delta, Roeselaere, Belgium; 11Department of Obstetrics and Gynaecology, Imelda Hospital, Bonheiden, BelgiumCorrespondence: Hava Izci, KU Leuven, Department of oncology, Herestraat 49 Box 7003-06, Leuven, 3000, Belgium, Email hava.izci@kuleuven.bePurpose: High-quality population-based cancer recurrence data are scarcely available, mainly due to complexity and cost of registration. For the first time in Belgium, we developed a tool to estimate distant recurrence after a breast cancer diagnosis at the population level, based on real-world cancer registration and administrative data.Methods: Data on distant cancer recurrence (including progression) from patients diagnosed with breast cancer between 2009– 2014 were collected from medical files at 9 Belgian centers to train, test and externally validate an algorithm (i.e., gold standard). Distant recurrence was defined as the occurrence of distant metastases between 120 days and within 10 years after the primary diagnosis, with follow-up until December 31, 2018. Data from the gold standard were linked to population-based data from the Belgian Cancer Registry (BCR) and administrative data sources. Potential features to detect recurrences in administrative data were defined based on expert opinion from breast oncologists, and subsequently selected using bootstrap aggregation. Based on the selected features, classification and regression tree (CART) analysis was performed to construct an algorithm for classifying patients as having a distant recurrence or not.Results: A total of 2507 patients were included of whom 216 had a distant recurrence in the clinical data set. The performance of the algorithm showed sensitivity of 79.5% (95% CI 68.8– 87.8%), positive predictive value (PPV) of 79.5% (95% CI 68.8– 87.8%), and accuracy of 96.7% (95% CI 95.4– 97.7%). The external validation resulted in a sensitivity of 84.1% (95% CI 74.4– 91.3%), PPV of 84.1% (95% CI 74.4– 91.3%), and an accuracy of 96.8% (95% CI 95.4– 97.9%).Conclusion: Our algorithm detected distant breast cancer recurrences with an overall good accuracy of 96.8% for patients with breast cancer, as observed in the first multi-centric external validation exercise.Keywords: machine learning, breast cancer, distant metastases, recurrences, algorithm, administrative data

Published
2023

2. Update on triple-negative breast cancer: prognosis and management strategies

Author

Brouckaert O, Wildiers H, Floris G, and Neven P

Subjects
Gynecology and obstetrics, RG1-991
Abstract

Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Patrick NevenMultidisciplinary Breast Centre, UZ Leuven, Leuven, BelgiumAbstract: Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%–20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a particular clinical presentation and outcome. All these features will be discussed in this review. The risk of developing TNBC varies with age, race, genetics, breastfeeding patterns, and parity. Some TNBC are very chemo-sensitive and the majority of patients confronted with and treated for TNBC will never relapse. Some (histological) subgroups of TNBC may have good prognosis even in the absence of chemotherapy. Distinct molecular subgroups within TNBC have been defined now as well. In case metastatic relapse occurs, this is usually within 5 years following surgery, and survival following metastatic relapse is shorter compared to other breast cancer subtypes; treatment options are few and responses lack durability. Novel drug targets and new biomarkers are needed to improve breast cancer care for patients presenting with TNBC. Further molecular/biological unraveling of TNBC is needed.Keywords: breast cancer, triple negative, review

Published
2012

3. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Author

Aebi, S., Al-Foheidi, M., André, F., Anikusko, M., Badwe, R., Barrio, A.V., Barrios, C., Bergh, J., Bonnefoi, H., Bretel Morales, D., Brucker, S., Burstein, H.J., Caldas, C., Cameron, D., Cardoso, F., Cardoso, M.J., Carey, L., Chia, S., Coles, C., Cortes, J., Curigliano, G., de Boniface, J., Delaloge, S., DeMichele, A., Denkert, C., Fastner, G., Fitzal, F., Francis, P., Gamal, H., Gentilini, O., Gnant, M., Gradishar, W., Gulluoglu, B., Harbeck, N., Heil, J., Huang, C.-S.H., Huober, J., Jiang, Z., Kaidar-Person, O., Kok, M., Lee, E.-S., Loi, S., Loibl, S., Martin, M., Meattini, I., Morrow, M., Partridge, A., Penault-Llorca, F., Piccart, M., Pierce, L., Poortmans, P., Regan, M., Reis-Filho, J., Rubio, I., Rugo, H., Rutgers, E., Saura, C., Senkus, E., Shao, Z., Singer, C., Spanic, T., Thuerlimann, B., Toi, M., Tolaney, S., Turner, N., Tutt, A., Vrancken Peeters, M.-J., Watanabe, T., Weber, W., Wildiers, H., Xu, B., Regan, M.M., Weber, W.P., and Thürlimann, B.

Published
2023
Full Text
View/download PDF

4. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Author

Jhaveri, K., Eli, L.D., Wildiers, H., Hurvitz, S.A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E.S., Spanggaard, I., Reid, S., Burkard, M.E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F.-C., Loi, S., Crown, J., Bhave, M., Piha-Paul, S.A., Suga, J.M., Chia, S., Saura, C., Garcia-Saenz, J.Á., Gambardella, V., de Miguel, M.J., Gal-Yam, E.N., Raphael, A., Stemmer, S.M., Ma, C., Hanker, A.B., Ye, D., Goldman, J.W., Bose, R., Peterson, L., Bell, J.S.K., Frazier, A., DiPrimeo, D., Wong, A., Arteaga, C.L., and Solit, D.B.

Published
2023
Full Text
View/download PDF

7. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

Author

Van Baelen, K., Geukens, T., Maetens, M., Tjan-Heijnen, V., Lord, C.J., Linn, S., Bidard, F.-C., Richard, F., Yang, W.W., Steele, R.E., Pettitt, S.J., Van Ongeval, C., De Schepper, M., Isnaldi, E., Nevelsteen, I., Smeets, A., Punie, K., Voorwerk, L., Wildiers, H., Floris, G., Vincent-Salomon, A., Derksen, P.W.B., Neven, P., Senkus, E., Sawyer, E., Kok, M., and Desmedt, C.

Published
2022
Full Text
View/download PDF

11. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

15. End-of-life healthcare utilization in older patients with cancer: a large Belgian data linkage study

Author

Depoorter, V., primary, Vanschoenbeek, K., additional, Decoster, L., additional, Silversmit, G., additional, Debruyne, P., additional, De Groof, I., additional, Bron, D., additional, Cornélis, F., additional, Luce, S., additional, Focan, C., additional, Verschaeve, V., additional, Debugne, G., additional, Langenaeken, C., additional, Van Den Bulck, H., additional, Goeminne, J.C., additional, Teurfs, W., additional, Jerusalem, G., additional, Schrijvers, D., additional, Petit, B., additional, Rasschaert, M., additional, Praet, J.P., additional, Vandenborre, K., additional, De Schutter, H., additional, Milisen, K., additional, Flamaing, J., additional, Kenis, C., additional, Verdoodt, F., additional, and Wildiers, H., additional

Published
2023
Full Text
View/download PDF

16. ICT-based oncogeriatric evaluation for management of older multimorbid patients: GerOnTe protocol

Author

Degol, L., primary, Hamaker, M., additional, Wildiers, H., additional, Ardito, V., additional, Barthod-Malat, A., additional, Davis, P., additional, Ferrara, L., additional, Kenis, C., additional, Kret, M., additional, Lalet, C., additional, Lehn, E., additional, Mathoulin-Pellissier, S., additional, O’hanlon, S., additional, O’sullivan, B., additional, Saillour-Glenisson, F., additional, Schwimmer, C., additional, Rostoft, S., additional, Staines, A., additional, Thevenet, V., additional, Vodjogbe, K., additional, Wallet, C., additional, and Soubeyran, P., additional

Published
2023
Full Text
View/download PDF

18. Palliative care at the end-of-life in older patients with cancer and associated age-related factors

Author

Depoorter, V., primary, Vanschoenbeek, K., additional, Decoster, L., additional, Silversmit, G., additional, Debruyne, P., additional, De Groof, I., additional, Bron, D., additional, Cornélis, F., additional, Luce, S., additional, Focan, C., additional, Verschaeve, V., additional, Debugne, G., additional, Langenaeken, C., additional, Van Den Bulck, H., additional, Goeminne, J.C., additional, Teurfs, W., additional, Jerusalem, G., additional, Schrijvers, D., additional, Petit, B., additional, Rasschaert, M., additional, Praet, J.P., additional, Vandenborre, K., additional, De Schutter, H., additional, Milisen, K., additional, Flamaing, J., additional, Kenis, C., additional, Verdoodt, F., additional, and Wildiers, H., additional

Published
2023
Full Text
View/download PDF

23. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

Author

Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J. C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., Specenier, P., Jerusalem, G., Praet, J. P., Vandenborre, K., Lycke, M., Flamaing, J., Milisen, K., Lobelle, J. P., and Wildiers, H.

Published
2019

25. 70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials

Author

Van Baelen, K., primary, Van Cauwenberge, J., additional, Maetens, M., additional, Camden, A., additional, Chase, M.C., additional, Fraser, V., additional, Freeney, S., additional, Hutcheson, L., additional, Levine, J.K., additional, Lien, T., additional, Terveer, R., additional, Turner, C., additional, Vandecaveye, V., additional, Neven, P., additional, Wildiers, H., additional, Sawyer, E., additional, Vincent-Salomon, A., additional, Derksen, P., additional, Desmedt, C., additional, and Beck, G., additional

Published
2023
Full Text
View/download PDF

26. 52P Clinical characterization of HER2 low in patients with lobular breast cancer (ILC)

Author

Van Baelen, K., primary, Nguyen, H.L., additional, Richard, F., additional, Zels, G., additional, Karsten, M.M., additional, Marta, G. Nader, additional, Vermeulen, P., additional, Dirix, L.Y., additional, Wuyts, H., additional, Dordevic, A.D., additional, de Azambuja, E., additional, Larsimont, D., additional, Maetens, M., additional, Biganzoli, E., additional, Wildiers, H., additional, Smeets, A., additional, Nevelsteen, I., additional, Neven, P., additional, Floris, G., additional, and Desmedt, C., additional

Published
2023
Full Text
View/download PDF

27. 14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status

Author

Richard, F., primary, De Schepper, M., additional, Geukens, T., additional, Vos, H., additional, Bassez, A., additional, Nguyen, H.L., additional, Maetens, M., additional, Wang, L., additional, Nevelsteen, I., additional, Wildiers, H., additional, Neven, P., additional, Punie, K., additional, Smeets, A., additional, Lambrechts, D., additional, Floris, G., additional, and Desmedt, C., additional

Published
2023
Full Text
View/download PDF

28. P004 - Essais randomisés en stepped-wedge - Leçons et défis de mise en œuvre avec l'exemple du projet GERONTE

Author

Thevenet, V., primary, Kret, M., additional, Arsandaux, J., additional, Ardito, V., additional, Degol, L., additional, Ferrara, L., additional, Hamaker, M., additional, Kenis, C., additional, Lehn, E., additional, Mathoulin-Pelissier, S., additional, Schwimmer, C., additional, Staines, A., additional, Vodjogbe, K., additional, Wallet, C., additional, Wildiers, H., additional, Soubeyran, P., additional, and Saillour-Glénisson, F., additional

Published
2023
Full Text
View/download PDF

30. 2MO Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)

Author

Pabba, A., primary, Zels, G., additional, De Schepper, M., additional, Geukens, T., additional, Van Baelen, K., additional, Maetens, M., additional, Nguyen, H.L., additional, Mahdami, A., additional, Boeckx, B., additional, Vanderheyden, E., additional, Punie, K., additional, Neven, P., additional, Wildiers, H., additional, Van Den Bogaert, W., additional, Biganzoli, E., additional, Lambrechts, D., additional, Floris, G., additional, Richard, F., additional, and Desmedt, C., additional

Published
2023
Full Text
View/download PDF

31. 40P Stromal tumor infiltrating lymphocytic infiltration in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)

Author

Pabba, A., primary, De Schepper, M., additional, Geukens, T., additional, Van Baelen, K., additional, Maetens, M., additional, Isnaldi, E., additional, Leduc, S., additional, Nguyen, H.L., additional, Mahdami, A., additional, Zels, G., additional, Van Cauwenberge, J., additional, Borremans, K., additional, Van Den Bogaert, W., additional, Punie, K., additional, Neven, P., additional, Wildiers, H., additional, Biganzoli, E., additional, Richard, F., additional, Floris, G., additional, and Desmedt, C., additional

Published
2023
Full Text
View/download PDF

36. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors

Author

van Cann, T., Loyson, T., Verbiest, A., Clement, P. M., Bechter, O., Willems, L., Spriet, I., Coropciuc, R., Politis, C., Vandeweyer, R. O., Schoenaers, J., Debruyne, P. R., Dumez, H., Berteloot, P., Neven, P., Nackaerts, K., Woei-A-Jin, F. J. S. H., Punie, K., Wildiers, H., and Beuselinck, B.

Published
2017
Full Text
View/download PDF

37. Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”

Author

Van Baelen, K., primary, Geukens, T., additional, Maetens, M., additional, Tjan-Heijnen, V., additional, Lord, C.J., additional, Linn, S., additional, Bidard, F.-C., additional, Richard, F., additional, Yang, W.W., additional, Steele, R.E., additional, Pettitt, S.J., additional, Van Ongeval, C., additional, De Schepper, M., additional, Isnaldi, E., additional, Nevelsteen, I., additional, Smeets, A., additional, Punie, K., additional, Voorwerk, L., additional, Wildiers, H., additional, Floris, G., additional, Vincent Salomon, A., additional, Derksen, P.W.B., additional, Neven, P., additional, Senkus, E., additional, Sawyer, E., additional, Kok, M., additional, and Desmedt, C., additional

Published
2022
Full Text
View/download PDF

38. Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases

Author

Wu, Q., primary, Hatse, S., additional, García, J., additional, Altea-Manzano, P., additional, Billen, J., additional, Planque, M., additional, Vandekeere, A., additional, Lambrechts, Y., additional, Richard, F., additional, Laenen, A., additional, Punie, K., additional, Neven, P., additional, Nevelsteen, I., additional, Floris, G., additional, Desmedt, C., additional, Gomes, A., additional, Fendt, S.M., additional, and Wildiers, H., additional

Published
2022
Full Text
View/download PDF

42. Hospitalizations, emergency department visits and home care in older patients after cancer diagnosis: results from a large data linkage study with 3 year follow-up

Author

Depoorter, V., primary, Vanschoenbeek, K., additional, Decoster, L., additional, De Schutter, H., additional, Debruyne, P.R., additional, De Groof, I., additional, Bron, D., additional, Cornélis, F., additional, Luce, S., additional, Focan, C., additional, Verschaeve, V., additional, Debugne, G., additional, Langenaeken, C., additional, Van Den Bulck, H., additional, Goeminne, J.C., additional, Teurfs, W., additional, Jerusalem, G., additional, Schrijvers, D., additional, Petit, B., additional, Rasschaert, M., additional, Praet, J.P., additional, Vandenborre, K., additional, Milisen, K., additional, Flamaing, J., additional, Kenis, C., additional, Verdoodt, F., additional, and Wildiers, H., additional

Published
2022
Full Text
View/download PDF

44. 1265MO Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data

Author

Depoorter, V., primary, Vanschoenbeek, K., additional, Decoster, L., additional, De Schutter, H., additional, Debruyne, P.R., additional, De Groof, I., additional, Bron, D., additional, Cornelis, F., additional, Luce, S., additional, Focan, C., additional, Verschaeve, V., additional, Debugne, G., additional, Langenaeken, C.M., additional, van den Bulck, H.F.M., additional, Goeminne, J-C., additional, Milisen, K., additional, Flamaing, J., additional, Kenis, C., additional, Verdoodt, F., additional, and Wildiers, H., additional

Published
2022
Full Text
View/download PDF

46. 171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer

Author

Marmé, F., primary, Wildiers, H., additional, Dirix, L., additional, Armstrong, A., additional, De Cuypere, E., additional, Dalenc, F., additional, Pia Schröder, C., additional, Vuylsteke, P., additional, Brain, E., additional, Kuemmel, S., additional, Pápai, Z., additional, Mueller, C., additional, Brignone, C., additional, and Triebel, F., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results